[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-441681-105":59,"doc-detail-441681-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","non-viral-gene-delivery-for-non-small-cell-lung-cancer","Non-viral gene delivery for non-small cell lung cancer","","Editorial commentary on drug and biomaterials screening and development, focusing on non-viral gene delivery for non-small cell lung cancer (NSCLC). The text describes the clinical challenge of improving cure and survival rates and highlights oncogenic drivers targeted by small interfering RNA (siRNA). It summarizes evaluation of cationic lipopolymers as nanocarriers for siRNA delivery to lung cancer cell models, emphasizing target genes involved in cell cycle regulation, apoptosis, and signaling. It also discusses PEI-based formulation strategies and screening approaches to optimize nanoparticle properties for nucleic acid therapy.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-viral-gene-delivery-for-non-small-cell-lung-cancer/441681/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-viral-gene-delivery-for-non-small-cell-lung-cancer/441681.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How does the commentary describe the screening process for lipopolymer formulations?","Question",{"text":112,"@type":113},"It explains that a library of 45 lipopolymer formulations was screened using a defined polymer-to-siRNA ratio and siRNA concentration in wild-type A549 cells. Top performers were down-selected and then used for aqueous incubation to generate nanoparticles with reported size and surface charge ranges.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},441681,1791442949,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":136,"preview_page_count":4},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Editorial Commentary | Drug and Biomaterials Screening and Development  \nNon-viral gene delivery for non-small cell lung cancer  \nVincent Fung1^, Nicole A. Gill1^, Sawyer Andersen2^, Owen S. Fenton1^  \n1Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Correspondence to: Owen S. Fenton, PhD. Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Marsico Hall Office 4214, 125 Mason Farm Road, Chapel Hill, NC 27599, USA. Email: [osfenton@unc.edu](osfenton@unc.edu). Comment on: Kc R, Nasrullah M, Sandhu G, et al. Cationic lipopolymer based siRNA delivery for experimental lung cancer treatment. Biomater Adv 2025;177:214394 .  \nKeywords: Lipopolymer; small interfering RNA lung delivery (siRNA lung delivery); nucleic acid therapeutics; polyethylenimine-based derivatives (PEI-based derivatives)  \nSubmitted Aug 22, 2025. Accepted for publication Nov 07, 2025. Published online Dec 24, 2025.  \ndoi: 10.21037/atm-25-127  \nView this article at: [https://dx.doi.org/10.21037/atm-25-127](https://dx.doi.org/10.21037/atm-25-127)  \nNon-small cell lung cancer (NSCLC) accounts for approximately 85% of total lung cancer cases and remains the most frequently diagnosed cancer worldwide, representing 11.4% of global cancer incidences and 18.0% of cancerrelated deaths as of 2020 (1,2) . Despite advances in targeted therapies and a deeper understanding of tumor biology, the overall cure and survival rates for NSCLC leave room for improvement, particularly for advanced stages of the disease (3) . Many oncogenic drivers implicated in NSCLC progression, such as KRAS, EGFR, MYC, VEGF, BCL2, MCL1, and STAT proteins, are considered challenging to target with conventional small-molecule drugs (4-6). Among these, CDC20, Survivin, and STAT5A have drawn increasing attention due to their roles in regulating cell division, inhibiting apoptosis, and promoting tumor proliferation (7-9). One promising strategy to counteract these drivers involves the delivery of therapeutic small interfering RNA (siRNA) to cancer cells, which may suppress oncogenic gene expression by facilitating degradation of the messenger RNA (mRNA) transcripts (10,11) . For this approach to be effective, careful selection of a suitable delivery vehicle is essential to ensure that the therapeutic siRNA reaches its target efficiently and exerts its intended biological effect (12,13) .  \nIn the article entitled “Cationic lipopolymer based  \nsiRNA delivery for experimental lung cancer treatment”, published in Biomaterials Advances, the authors present interesting findings on a novel class of commercially available cationic lipopolymers as nanocarriers for siRNA delivery as an experimental lung cancer treatment (1) . In this study, three of these cationic lipopolymer reagents, ALL-Fect, Leu-Fect, and Prime-Fect, were evaluated as siRNA nanocarriers that targeted CDC20, Survivin, and STAT5A, which serve as key regulators of cell cycle progression, apoptosis inhibition, and transcriptional signalling, respectively (1) . The authors evaluated these lipopolymers in vitro with three human lung cancer model cell lines: A549 wild type, A549-luc, and Calu-3 (1) .  \nPolyethylenimine (PEI) derivatives have been used as transfection reagents in preclinical research. PEI derivatives may have room for opportunities to enter the clinical stage with molecule re-design and modification (10) . Building on this, Kc [et al.](et al. report)[ report](et al. report) data that positions three commercially available lipopolymer formulations, ALL-Fect, LeuFect, and Prime-Fect, as potential nanocarriers for siRNA delivery in NSCLC treatment (1) . Their work reopens the discussion around delivery platforms that could offer new solut","cbCaiuRzs56yvUSZ","https://ap.wps.com/l/cbCaiuRzs56yvUSZ","pdf",133300,"English","# Background: NSCLC challenge and siRNA rationale\n# Review of cationic lipopolymer nanocarriers and target genes\n# PEI-based delivery platforms and formulation directions\n# Screening design and down-selection workflow","[{\"question\":\"How does the commentary describe the screening process for lipopolymer formulations?\",\"answer\":\"It explains that a library of 45 lipopolymer formulations was screened using a defined polymer-to-siRNA ratio and siRNA concentration in wild-type A549 cells. Top performers were down-selected and then used for aqueous incubation to generate nanoparticles with reported size and surface charge ranges.\"}]","Non-viral gene delivery for non-small cell lung cancer | PDF",1790697074,13]